Nonalcoholic Fatty Liver Disease

New Insights

Ramón Anibal Rodrigo Salinas (Herausgeber)

Buch | Hardcover

137 Seiten

2016
Nova Science Publishers Inc (Verlag)
978-1-63484-217-4 (ISBN)

Artikel merken

Non-alcoholic fatty liver disease, or NAFLD, represents a spectrum of pathologic liver histologic findings ranging from the simple accumulation of fat, known as steatosis, to nonalcoholic steatohepatitis and cirrhosis. It is estimated that NAFLD in all of its forms would have a 20% prevalence worldwide, but the evidence suggests a higher rate for developed countries, exceeding 30% for the US general population. Major risk factors for NAFLD, such as ageing, obesity and insulin resistance, are projected to increase in the following decades, causing the prevalence and relevance of NAFLD to rise in the future. In obese populations and type 2 diabetes patients, the prevalence of this disease exceeds 70%. NAFLD has been called the "silent epidemic" for its lack of symptoms, relatively complex diagnosis and its deleterious effects. The association between NAFLD with cardiovascular diseases, energy metabolism disorders and polycystic ovarian syndrome has promoted the inclusion of this liver pathology within the metabolic syndrome. From a biochemical point of view, current evidence suggests the existence of a bidirectional causal relationship between NAFLD and oxidative stress, where various alterations energy metabolism and important inflammatory components are involved. An abnormal glucose and fatty acid metabolism lead to glucotoxicity and lipotoxicity, respectively, which promote oxidative stress through different pathways. Oxidative stress induces the expression of pro-inflammatory mediators, including transcription factors and cytokines, which trigger an immune activation, a key step in the transition from simple steatosis to steatohepatitis. An early diagnosis and optimal therapy are essential for NAFLD treatment. First-line treatment of NAFLD focuses on lifestyle changes. Weight reduction through an increase in physical activity and/or nutritional management is considered safe and effective, but pharmacological management of common comorbidities such as hyperglycemia, dyslipidemias and hypertension are also essential. The key role of oxidative stress in NAFLD pathophysiology suggests that antioxidant interventions based in natural substances such as polyphenols would be effective. Recently, it was shown that the antioxidant properties of these compounds are beyond their free radical scavenging. This book presents an update of research advances contributing to a better understanding of relevant clinical models of NAFLD, particularly, the disorder in energy metabolism and the role of oxidative stress. It also highlights the clinical and pathophysiological association between NAFLD and the metabolic syndrome, and presents an overview of current diagnosis and treatment and the future avenues for the management of this disease.

Preface; Current Diagnosis & Therapy in Nonalcoholic Fatty Liver Disease; Molecular Mechanisms in the Development & Progression of Nonalcoholic Fatty Liver Disease; Role of Oxidative Stress & Inflammation in the Pathophysiology of Nonalcoholic Fatty Liver Disease; Non-Alcoholic Fatty Liver Disease & the Metabolic Syndrome; Non-Alcoholic Fatty Liver Disease: Novel Therapeutic Approaches; The Potential Role of Polyphenols in Nonalcoholic Fatty Liver Disease Treatment; Index.

Erscheinungsdatum	08.01.2016
Verlagsort	New York
Sprache	englisch
Maße	155 x 230 mm
Gewicht	372 g
Themenwelt	Medizinische Fachgebiete ► Innere Medizin ► Hepatologie
ISBN-10	1-63484-217-0 / 1634842170
ISBN-13	978-1-63484-217-4 / 9781634842174
Zustand	Neuware